Who We Are
Prelude is a privately-held, clinical-stage biopharmaceutical company designing and developing a pipeline of novel, orally bioavailable, small molecule therapies that target key drivers of cancer cell growth, survival and resistance.
Proven track record of developing successful drugs
Extensive experience in rapidly advancing concepts to clinical candidates
Highly focused on addressing mechanisms of resistance to targeted agents
We are focused on closing the gap between emerging insights into resistance mechanisms in cancer and the needs of patients who fail current cancer treatments. Today’s precision medicines targeting known drivers of tumor growth are highly effective initially, but many patients inevitably develop a resistance to these therapies.
There is an urgent need for medicines that can target critical intervention points in pathways of resistance to overcome treatment failure in cancer. With our strong expertise in cancer biology, medicinal chemistry, and drug development, we are poised to translate the new discoveries into potential treatments that offer hope to people with cancer.
Our approach to the discovery and development of future oncology therapies embraces the concepts of design thinking and focuses on patients whose cancers are not responsive to or have become resistant to existing treatments.
We target mechanisms with genetic, preclinical, or clinical validation of driving resistance to current therapies, agnostic to target class or complexity of chemistry. Our knowledgeable and experienced team works in a nimble, energetic, and creative environment in order to move efficiently from ideas to design, synthesis, and testing of molecules we create. Our collaborative culture extends beyond our walls, as we work closely with preeminent academic institutions to identify opportunities and develop a pipeline of medicines to benefit patients with cancer.